{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Moore CB"],"funding":["National Institute of Allergy and Infectious Diseases","NICHD NIH HHS","NIAID NIH HHS","National Institute of Mental Health","National Institutes of Health","National Institute of Child Health and Human Development"],"pagination":["e191-e200"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12087306"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(3)"],"pubmed_abstract":["Background
Long-acting cabotegravir and long-acting rilpivirine constitute a completely intramuscular antiretroviral therapy (ART) regimen for adults with HIV. We aimed to assess the safety, antiviral activity, and pharmacokinetics of oral cabotegravir and rilpivirine followed by a combination of long-acting cabotegravir and long-acting rilpivirine in virologically suppressed adolescents with HIV.Methods
The IMPAACT 2017/MOCHA study is a phase 1/2, multicentre, open-label, non-comparative, dose-finding trial being conducted at 18 sites across Botswana, South Africa, Thailand, Uganda, and the USA. In cohort 2 of this study, adolescents (aged 12-18 years; weight ≥35 kg) with HIV and no serious comorbidities who were receiving stable combination ART with confirmed virological "],"journal":["The lancet. HIV"],"pubmed_title":["Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study."],"pmcid":["PMC12087306"],"funding_grant_id":["UM1 AI068632","UM1 AI106716","UM1AI068616","UM1 AI069536","HHSN275201800001I","UM1AI106716","U01 AI069530","UM1 AI068616","HHSN275201800001C","UM1AI068632","UM1 AI069399","UM1 AI069530"],"pubmed_authors":["Zabih S","Whitson K","Han K","Marzinke MA","Huang J","Lin YW","Buisson S","Korutaro V","Paul ME","Violari A","Van Eygen V","Ward S","Van Solingen-Ristea RM","Crauwels H","Masheto G","Moye JH","Gaur AH","Whitton M","Best BM","Hanley S","Aurpibul L","Patel F","Lowenthal ED","Agwu AL","Capparelli EV","Townley E","McCoig C","Harrington CM","Cheung SYA","Ford SL","Ounchanum P","Vandermeulen K","Moore CB","Heckman B","Krotje C","Milligan R","Yin DE","Deprez I","IMPAACT 2017 Collaborators for the IMPAACT 2017 Team","Baltrusaitis K","Roberts G","Collins JW"],"additional_accession":[]},"is_claimable":false,"name":"Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.","description":"Background
Long-acting cabotegravir and long-acting rilpivirine constitute a completely intramuscular antiretroviral therapy (ART) regimen for adults with HIV. We aimed to assess the safety, antiviral activity, and pharmacokinetics of oral cabotegravir and rilpivirine followed by a combination of long-acting cabotegravir and long-acting rilpivirine in virologically suppressed adolescents with HIV.Methods
The IMPAACT 2017/MOCHA study is a phase 1/2, multicentre, open-label, non-comparative, dose-finding trial being conducted at 18 sites across Botswana, South Africa, Thailand, Uganda, and the USA. In cohort 2 of this study, adolescents (aged 12-18 years; weight ≥35 kg) with HIV and no serious comorbidities who were receiving stable combination ART with confirmed virological ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-07-16T23:23:30.39Z","creation":"2026-07-12T03:11:02.547Z"},"accession":"S-EPMC12087306","cross_references":{"pubmed":["40049924"],"doi":["10.1016/S2352-3018(24)00344-8","10.1016/s2352-3018(24)00344-8"]}}